Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ATNM-400, a novel, non-PSMA targeting, first in ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply ...

Actinium announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy for prostate cancer utilizing the Actinium-225 ...

Actinium Pharma inks supply agreement with Eckert & Ziegler for Ac-225 radioisotope to support comprehensive development activities: New York Wednesday, March 26, 2025, 18:00 Hrs ...

today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler ...

EQS-News: Eckert & Ziegler SE / Key word (s): Agreement/Incoming Orders Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 ...

Investing.com — Actinium制药公司（NYSE AMERICAN: ATNM），一家专注于靶向放射治疗的公司，已从Eckert & Ziegler获得了放射性同位素锕-225（Ac-225）的供应，旨在推进其国内外癌症治疗的临床试验。

Agreement/Incoming OrdersEckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 CET/CESTThe issuer is solely responsible for the ...

Actinium Pharmaceuticals, Inc.  (Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it will be presenting a business update today at Trump Mar-a-Lago Club, ...